There are more than 260 genes known to cause inherited retinal diseases, and @OpusGenetics’ discovery and development work are leaving none of those stones unturned.
Featuring Ben Yerxa
#retinaldisease#biopharma#genetherapy#venturephilanthropy
https://t.co/IQbclmQXvl
In #FDAGuidance, “#nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.
https://t.co/OBUzLdyUkU
Computer-aided 3D modeling enables quick assessment of previously undiscovered protein binding sites and helps scientists at @GainThera marry them to the correct therapeutic molecules. Find out how.
https://t.co/NwCYrOSuwH
It is astonishing how often pharmas & biotechs commit similar or even the same #GMP mistakes — in (almost) always the same places. Here are two of the most common pitfalls to avoid: inadequate handling of deviations & inadequate handling of changes.
https://t.co/JacnLsmuMJ
We have entered a new age in #biologics development, which is undergoing a technological revolution with an increasing focus on software-dependent and data-driven results.
By @itiscolossal
#biologics#drugdiscovery#computationalscience
https://t.co/swL8rDGVi7
There are more than 260 genes known to cause inherited retinal diseases, and @OpusGenetics’ discovery and development work are leaving none of those stones unturned.
Featuring Ben Yerxa
#retinaldisease#biopharma#genetherapy#venturephilanthropy
https://t.co/IQbclmQXvl
@AviadoBio is building a pipeline of investigational gene therapies for neurodegenerative diseases. Its lead preclinical candidate is AVB-101 for GRN frontotemporal dementia, an intra-thalamic gene supplementation therapy.
#entrepreneur#womeninbio
https://t.co/uo9MPl5HxI
Why are #RNABasedTherapeutics seeing more patent activity now, and how should biotech companies mitigate patent risks? Attorneys from @NGE_Law share their insights.
https://t.co/Vf5Yh7Jajs
You read, watch, listen, travel to conferences & events, and learn from all of it. But none of those is the leading information source for those seeking it. What medium do most biopharma leaders seek when it’s learning they’re yearning for? Conversation.
https://t.co/E7pmaChCZC
On #BusinessOfBiotech#podcast, @AkariTX's @RachelleJ7k discusses the redeeming qualities of #tick saliva and how her company is putting it to work to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy.
https://t.co/c0e1qrbmFj
In #FDAGuidance, “#nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.
https://t.co/OBUzLdyUkU